Terms: = Astrocytoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
2161 results:
1. A syngeneic spontaneous zebrafish model of
Weiss A; D'Amata C; Pearson BJ; Hayes MN
Elife; 2024 Jul; 13():. PubMed ID: 39052000
[TBL] [Abstract] [Full Text] [Related]
2. Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.
Tarabini RF; Fioravanti Vieira G; Rigo MM; de Souza APD
Sci Rep; 2024 Jul; 14(1):16721. PubMed ID: 39030304
[TBL] [Abstract] [Full Text] [Related]
3. Targeting MDM2-p53 interaction in Glioblastoma: Transcriptomic analysis and Peptide-Based inhibition strategy.
Han M; Kakar M; Li W; Iqbal I; Hu X; Liu Y; Tang Q; Sun L; Shakir Y; Liu T
Bioorg Chem; 2024 Sep; 150():107620. PubMed ID: 38991490
[TBL] [Abstract] [Full Text] [Related]
4. A case series of osseous metastases in patients with glioblastoma.
Webb LM; Webb MJ; Campian JL; Caron SJ; Ruff MW; Uhm JH; Sener U
Medicine (Baltimore); 2024 Jul; 103(27):e38794. PubMed ID: 38968484
[TBL] [Abstract] [Full Text] [Related]
5. Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence.
Joruiz SM; Von Muhlinen N; Horikawa I; Gilbert MR; Harris CC
Cell Death Dis; 2024 Jun; 15(6):454. PubMed ID: 38937431
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of Microvascular Density in Glioblastomas in Relation to p53 and Ki67 Immunoexpression.
Sipos TC; Kövecsi A; Kocsis L; Nagy-Bota M; Pap Z
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928515
[TBL] [Abstract] [Full Text] [Related]
7. ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in tp53-mutant glioblastoma.
Laverty DJ; Gupta SK; Bradshaw GA; Hunter AS; Carlson BL; Calmo NM; Chen J; Tian S; Sarkaria JN; Nagel ZD
Nat Commun; 2024 Jun; 15(1):5294. PubMed ID: 38906885
[TBL] [Abstract] [Full Text] [Related]
8. IMPDH Inhibition Decreases TERT Expression and Synergizes the Cytotoxic Effect of Chemotherapeutic Agents in Glioblastoma Cells.
Liu X; Wang J; Wu LJ; Trinh B; Tsai RYL
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892179
[TBL] [Abstract] [Full Text] [Related]
9. Reprogramming Glioblastoma Cells into Non-Cancerous Neuronal Cells as a Novel Anti-Cancer Strategy.
Jiang MQ; Yu SP; Estaba T; Choi E; Berglund K; Gu X; Wei L
Cells; 2024 May; 13(11):. PubMed ID: 38891029
[TBL] [Abstract] [Full Text] [Related]
10. Metastatic glioblastoma to the lungs: a case report and literature review.
Yuen CA; Pekmezci M; Bao S; Kong XT
CNS Oncol; 2024 Jun; 13(1):2351789. PubMed ID: 38864820
[TBL] [Abstract] [Full Text] [Related]
11. Racial Disparities in Glioblastoma Genomic Alterations: A Comprehensive Analysis of a Multi-Institution Cohort of 2390 Patients.
John D; Alshalalfa M; Almeida T; Murray A; Marques J; Azzam G; Mellon EA; Benjamin CG; Komotar RJ; Ivan M; Mahal B; Rich BJ
World Neurosurg; 2024 Aug; 188():e625-e630. PubMed ID: 38843966
[TBL] [Abstract] [Full Text] [Related]
12. Molecular Pathology of Gliomas.
Galbraith K; Snuderl M
Clin Lab Med; 2024 Jun; 44(2):149-159. PubMed ID: 38821638
[TBL] [Abstract] [Full Text] [Related]
13. Exposure to Low-Frequency Radiation Changes the Expression of Nestin, VEGF, BCRP and Apoptosis Markers During Glioma Treatment Strategy: An
Amirinejad M; Eftekhar-Vaghefi SH; Nematollahi Mahani SN; Salari M; Yahyapour R; Ahmadi-Zeidabadi M
Curr Radiopharm; 2024; 17(1):55-67. PubMed ID: 38817005
[TBL] [Abstract] [Full Text] [Related]
14. Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme.
Feng Y; Wang Y; Li X; Sun Z; Qiang S; Wang H; Liu Y
Molecules; 2024 May; 29(10):. PubMed ID: 38792257
[TBL] [Abstract] [Full Text] [Related]
15. NEK2 promotes tp53 ubiquitination to enhance the proliferation and migration of tp53 wild-type glioblastoma cells.
Zhang Y; Yu H; He M; Liu W; Xiao S; Wang X; Huang P; Huang Q
Neoplasma; 2024 Jun; 71(3):255-265. PubMed ID: 38764296
[TBL] [Abstract] [Full Text] [Related]
16. Principles in the Management of Glioblastoma.
Roda D; Veiga P; Melo JB; Carreira IM; Ribeiro IP
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674436
[TBL] [Abstract] [Full Text] [Related]
17. Genomic landscape of glioblastoma without IDH somatic mutation in 42 cases: a comprehensive analysis using RNA sequencing data.
Okamoto T; Mizuta R; Takahashi Y; Otani Y; Sasaki E; Horio Y; Kuroda H; Matsushita H; Date I; Hashimoto N; Masago K
J Neurooncol; 2024 May; 167(3):489-499. PubMed ID: 38653957
[TBL] [Abstract] [Full Text] [Related]
18. Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype.
Dundar B; Alsawas M; Masaadeh A; Conway K; Snow AN; Sompallae RR; Bossler AD; Ma D; Lopes Abath Neto O
Pathol Res Pract; 2024 May; 257():155272. PubMed ID: 38631135
[TBL] [Abstract] [Full Text] [Related]
19. DKK3 Expression in Glioblastoma: Correlations with Biomolecular Markers.
Caffo M; Casili G; Caruso G; Barresi V; Campolo M; Paterniti I; Minutoli L; Ius T; Esposito E
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612910
[TBL] [Abstract] [Full Text] [Related]
20. The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.
Nakagawa-Saito Y; Mitobe Y; Togashi K; Suzuki S; Sugai A; Takenouchi S; Nakamura K; Sonoda Y; Kitanaka C; Okada M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612758
[TBL] [Abstract] [Full Text] [Related]
[Next]
